Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia

20Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.
Get full text

Abstract

S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson’s correlation coefficients. Mean plasma S100B was significantly higher in the patient group than in the control group. There were no significant correlations between plasma S100B and psychotic symptoms or cognition.

Cite

CITATION STYLE

APA

Deng, H., Kahlon, R. S., Mohite, S., Amin, P. A., Zunta-Soares, G., Colpo, G. D., … Okusaga, O. O. (2018). Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia. Psychiatric Quarterly, 89(1), 53–60. https://doi.org/10.1007/s11126-017-9514-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free